EGFR and neoplasm: PD-L1 expression, TMB, and gene alterations were assessed in 50 tumour samples from patients with metastatic NSCLC, obtained at the time of diagnosis, prior to therapy, previously tested according to a standard clinical protocol by PCR, and negative for EGFR mutation.